IOD1 over-expression in sentinel lymph nodes of melanoma patients reduces the efficacy of anti-CTLA-1-4 and anti-PD1/PD-L1 therapy, and leads to reduced lymphocyte infiltration at the tumor site and poor prognosis [46]. This evidence concerns the gene PDCD1 and neoplasm.